EKS declares no competing interests. WDT reports consulting fees from Eli Lilly, Daiichi Sankyo, Deciphera, Foghorn Therapeutics, AmMAx Bio, Novo Holdings, Servier, Medpacto, Ayala Pharmaceuticals, Kowa Research Institute, Epizyme (Nexus Global Group), Bayer, Cogent Biosciences, Amgen, Physicians’ Education Resource, and BioAlta on the development of novel agents for the treatment of patients with sarcomas; has a patent Companion Diagnostic for CDK4 inhibitors (14/854,329) for the treatment of liposarcoma; holds stock options in and is a member of the scientific advisory boards for Certis Oncology Solutions, a life science technology company working on orthotopic patient-derived xenografts in oncology; and holds stock options in and is a co-founder and director of Atropos Therapeutics, a company that focuses on a drug discovery platform to identify chemical matter that can modulate the formation of senescent cells in relation to ageing and oncology. None of WDT's competing interests are related to the topic discussed here. WDT is the 2022 President of the Connective Tissue Oncology Society.